Bono invests in biotech? Peptide player is headed to the US — with celebrity investors backing its move
Even celebrities are piqued by biotech these days. For Bono and The Edge, it appears they’ve found what they’re looking for — and they’re willing to put their money on it.
The Irish peptide biotech Nuritas closed a $45 million Series B, an event which gained some added exposure through their front men from Dublin: U2’s The Edge and the man himself — Bono.
Nuritas’s round, led by Chicago-based investor Cleveland Avenue, includes the European Circular Bioeconomy Fund (ECBF), Vertex Holdings and more. The Series B also more than doubles what Nuritas had raised previously, bringing the biotech to $75 million raised in total.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 124,400+ biopharma pros reading Endpoints daily — and it's free.